Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C7WO
|
||||
| Former ID |
DPR000003
|
||||
| Drug Name |
1192U90
|
||||
| Synonyms |
LS-25359; 2-Amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide; 2-Amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl] benzamide; 2-amino-N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Psychotic disorders [ICD9: 290-299; ICD10:F20-F29] | Phase 1 | [1] | ||
| Schizophrenia [ICD9: 295; ICD10:F20] | Terminated | [2] | |||
| Company |
GlaxoSmithKline
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H27N5OS
|
||||
| Canonical SMILES |
C1CN(CCN1CCCCNC(=O)C2=CC=CC=C2N)C3=NSC4=CC=CC=C43
|
||||
| InChI |
1S/C22H27N5OS/c23-19-9-3-1-7-17(19)22(28)24-11-5-6-12-26-13-15-27(16-14-26)21-18-8-2-4-10-20(18)29-25-21/h1-4,7-10H,5-6,11-16,23H2,(H,24,28)
|
||||
| InChIKey |
GMDXHLCLNHCEIC-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 155289-31-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [2] | |
| 5-hydroxytryptamine 1A receptor | Target Info | Agonist | [2] | ||
| 5-hydroxytryptamine 2A receptor | Target Info | Antagonist | [2] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholismhsa04024:cAMP signaling pathway | |||||
| Serotonergic synapsehsa04020:Calcium signaling pathway | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| 5HT1 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic NeuronsWP722:Serotonin HTR1 Group and FOS Pathway | |||||
| SIDS Susceptibility Pathways | |||||
| GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | 1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects. Neuropsychopharmacology. 1996 Sep;15(3):231-42. | ||||
| REF 2 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.